Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
BioCentury
|
Mar 18, 2013
Clinical News
Limtop imiquimod: Development discontinued
...showed that Limtop did not meet the predefined efficacy target. Moberg declined to disclose details.
Moberg Derma AB
...
Read More
BioCentury
|
Dec 3, 2012
Company News
Alterna, Moberg Derma deal
...nail topical solution under Alterna's brand name Kerasal Nail. Alterna LLC , Cedar Knolls, N.J.
Moberg Derma AB
...
Read More
BioCentury
|
Sep 10, 2012
Clinical News
Limtop imiquimod: Completed Phase II enrollment
...placebo-controlled, German Phase II trial evaluating topical Limtop given 1, 3 or 7 times weekly.
Moberg Derma AB
...
Read More
BioCentury
|
Aug 6, 2012
Finance
Glint of IPO optimism
...17% -60% -2% -58% RaQualia Pharma Inc. (JASDAQ:4579) 7/8/11 $79.4 -79% 10% -89% -68% -64%
Moberg Derma AB
...
Read More
BioCentury
|
Mar 19, 2012
Clinical News
Limtop: Phase I started
...Derma began a double-blind, placebo-controlled, German Phase I trial to evaluate Limtop in 30 subjects.
Moberg Derma AB
...
Read More
BioCentury
|
Mar 19, 2012
Finance
Highlights of weekly biotech stock moves
...on March 12, before the company proposed to raise $175 million in a note offering.
Moberg Derma AB
...
Read More
BioCentury
|
Feb 20, 2012
Clinical News
MOB-015: Preliminary Phase II data
...by year end. Last year, the company completed enrollment of 237 patients in the trial.
Moberg Derma AB
...
Read More
BioCentury
|
Oct 3, 2011
Finance
Cost averaging down
...NASDAQ:HZNP) 7/28/11 $49.5 $171.9 $136.5 -21% Raqualia Pharma Inc. (JASDAQ:4579) 7/8/11 $79.4 $263.2 $95.1 -64%
Moberg Derma AB
...
Read More
BioCentury
|
Sep 19, 2011
Clinical News
MOB-015: Completed Phase II enrollment
...enrollment of 237 patients in an open-label, Swedish Phase II trial evaluating once-daily topical MOB-015.
Moberg Derma AB
...
Read More
BioCentury
|
Jul 4, 2011
Finance
3Q Financial Markets Preview: Hoping the rally has legs
...$2,990.2 $20,396.2 $23,307.2 7% (C) IPO performance Company Date Raised Post-$ 6/30 mcap % chg
Moberg Derma AB
...
Read More
Items per page:
10
1 - 10 of 32
BioCentury
|
Mar 18, 2013
Clinical News
Limtop imiquimod: Development discontinued
...showed that Limtop did not meet the predefined efficacy target. Moberg declined to disclose details.
Moberg Derma AB
...
Read More
BioCentury
|
Dec 3, 2012
Company News
Alterna, Moberg Derma deal
...nail topical solution under Alterna's brand name Kerasal Nail. Alterna LLC , Cedar Knolls, N.J.
Moberg Derma AB
...
Read More
BioCentury
|
Sep 10, 2012
Clinical News
Limtop imiquimod: Completed Phase II enrollment
...placebo-controlled, German Phase II trial evaluating topical Limtop given 1, 3 or 7 times weekly.
Moberg Derma AB
...
Read More
BioCentury
|
Aug 6, 2012
Finance
Glint of IPO optimism
...17% -60% -2% -58% RaQualia Pharma Inc. (JASDAQ:4579) 7/8/11 $79.4 -79% 10% -89% -68% -64%
Moberg Derma AB
...
Read More
BioCentury
|
Mar 19, 2012
Clinical News
Limtop: Phase I started
...Derma began a double-blind, placebo-controlled, German Phase I trial to evaluate Limtop in 30 subjects.
Moberg Derma AB
...
Read More
BioCentury
|
Mar 19, 2012
Finance
Highlights of weekly biotech stock moves
...on March 12, before the company proposed to raise $175 million in a note offering.
Moberg Derma AB
...
Read More
BioCentury
|
Feb 20, 2012
Clinical News
MOB-015: Preliminary Phase II data
...by year end. Last year, the company completed enrollment of 237 patients in the trial.
Moberg Derma AB
...
Read More
BioCentury
|
Oct 3, 2011
Finance
Cost averaging down
...NASDAQ:HZNP) 7/28/11 $49.5 $171.9 $136.5 -21% Raqualia Pharma Inc. (JASDAQ:4579) 7/8/11 $79.4 $263.2 $95.1 -64%
Moberg Derma AB
...
Read More
BioCentury
|
Sep 19, 2011
Clinical News
MOB-015: Completed Phase II enrollment
...enrollment of 237 patients in an open-label, Swedish Phase II trial evaluating once-daily topical MOB-015.
Moberg Derma AB
...
Read More
BioCentury
|
Jul 4, 2011
Finance
3Q Financial Markets Preview: Hoping the rally has legs
...$2,990.2 $20,396.2 $23,307.2 7% (C) IPO performance Company Date Raised Post-$ 6/30 mcap % chg
Moberg Derma AB
...
Read More
Items per page:
10
1 - 10 of 32
Previous page
Next page